IL316663A - Salt and crystal forms of epidermal growth factor receptor inhibitor - Google Patents

Salt and crystal forms of epidermal growth factor receptor inhibitor

Info

Publication number
IL316663A
IL316663A IL316663A IL31666324A IL316663A IL 316663 A IL316663 A IL 316663A IL 316663 A IL316663 A IL 316663A IL 31666324 A IL31666324 A IL 31666324A IL 316663 A IL316663 A IL 316663A
Authority
IL
Israel
Prior art keywords
salt
growth factor
factor receptor
epidermal growth
crystal forms
Prior art date
Application number
IL316663A
Other languages
English (en)
Hebrew (he)
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of IL316663A publication Critical patent/IL316663A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL316663A 2022-05-04 2023-05-04 Salt and crystal forms of epidermal growth factor receptor inhibitor IL316663A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
IL316663A true IL316663A (en) 2024-12-01

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316663A IL316663A (en) 2022-05-04 2023-05-04 Salt and crystal forms of epidermal growth factor receptor inhibitor

Country Status (12)

Country Link
US (1) US20250282761A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519254A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517634A (cg-RX-API-DMAC7.html)
KR (1) KR20250012078A (cg-RX-API-DMAC7.html)
CN (1) CN119923392A (cg-RX-API-DMAC7.html)
AU (1) AU2023265064A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251624A1 (cg-RX-API-DMAC7.html)
IL (1) IL316663A (cg-RX-API-DMAC7.html)
MX (1) MX2024013485A (cg-RX-API-DMAC7.html)
TW (1) TW202409016A (cg-RX-API-DMAC7.html)
UY (1) UY40256A (cg-RX-API-DMAC7.html)
WO (1) WO2023215431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202432143A (zh) * 2022-11-01 2024-08-16 美商纜圖藥品公司 用於治療癌症之egfr抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
EP4237418B1 (en) * 2020-10-30 2026-02-11 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
EP4237088A1 (en) * 2020-10-30 2023-09-06 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
UY40256A (es) 2023-11-15
JP2025517634A (ja) 2025-06-10
AU2023265064A1 (en) 2024-11-14
TW202409016A (zh) 2024-03-01
EP4519254A1 (en) 2025-03-12
MX2024013485A (es) 2024-12-06
KR20250012078A (ko) 2025-01-23
WO2023215431A1 (en) 2023-11-09
US20250282761A1 (en) 2025-09-11
CN119923392A (zh) 2025-05-02
CA3251624A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
IL309469A (en) Salt and crystal forms of epidermal growth factor receptor inhibitor
IL317847A (en) Salts of SOS1 inhibitors
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
SG11202109438TA (en) A salt and crystal form of a fak inhibitor
IL321357A (en) KIF18A inhibitors and their uses
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL319748A (en) PCSK9 inhibitors and methods of using them
EP4222151A4 (en) PROTEIN ALPHA KINASE 1 INHIBITORS AND METHODS OF USE
EP4244231A4 (en) CRYSTALLINE SOLID MEGLUMIN SALT INHIBITOR OF BCL AND METHOD OF PREPARING AND USING THE SAME
EP3969442A4 (en) Inhibitors of fibroblast growth factor receptor kinases
IL318393A (en) Azaquinazoline compounds and methods of use
EP4329735A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
IL309447A (en) Pharmaceutical preparations of epidermal growth factor receptor inhibitor
EP4329766A4 (en) RIPK1 INHIBITORS AND METHODS OF USE
EP4148055A4 (en) CRYSTAL FORM OF A MACROCYCLIC TYROSINE KINASE INHIBITOR AND PROCESS FOR PRODUCTION THEREOF
HK40124180A (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
EP4161488A4 (en) RHO-KINASE INHIBITOR RELEASING IMPLANTS AND RELATED METHODS OF USE
AU2024397820A1 (en) Vps34 inhibitors and methods of use thereof
CA3280370A1 (en) Crystal form and use of parp7 inhibitor and salt thereof
EP4438606A4 (en) NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT
EP4458821A4 (en) Salt form and crystal form of a tetrahydrocyclohepta-indazole compound
CA3298336A1 (en) Salt of thiazolopyrazine compound or crystal thereof and use thereof
CA3278084A1 (en) Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof
HK40130329A (en) Salt form and crystal form of plk1 kinase inhibitor, and preparation method therefor and use thereof
CA3271284A1 (en) Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof